ADVFN US – Market Content Editor

NextEra Energy (NYSE:NEE) climbed 2.85% on Monday after unveiling a major expansion of its collaboration with Google Cloud aimed at developing multiple gigawatt-scale data center campuses across the United States. Under the expanded partnership, the two companies will jointly build data centers along with the generation and capacity infrastructure needed to support them. Google Cloud…

Recursion Pharmaceuticals (NASDAQ:RXRX) gained 7% on Monday after releasing encouraging Phase 2 results for REC-4881, its investigational therapy for familial adenomatous polyposis (FAP)—a hereditary condition that currently has no approved treatments. According to the company, REC-4881 showed rapid and meaningful clinical activity. Three-quarters of evaluable patients experienced a decrease in total polyp burden, with a…

Wave Life Sciences Ltd. (NASDAQ:WVE) soared 40% on Monday after releasing interim findings from its Phase 1 INLIGHT study evaluating WVE-007, an investigational therapy targeting obesity. A single 240 mg dose of WVE-007 produced notable improvements in body composition over a three-month period. Participants experienced a 9.4% reduction in visceral fat, a 4.5% decrease in…

Marvell Technology (NASDAQ:MRVL) slid 6% on Monday amid growing concerns that the semiconductor firm may be losing key hyperscaler design wins. The drop followed a report indicating Microsoft (NASDAQ:MSFT) is exploring future custom chip development with Broadcom (NASDAQ:AVGO), as well as a downgrade from Benchmark over worries about Amazon (NASDAQ:AMZN) shifting away from Marvell. According…

Kymera Therapeutics (NASDAQ:KYMR) jumped 16% on Monday after the company reported promising early-stage clinical results for KT-621, its oral STAT6 degrader being developed for moderate to severe atopic dermatitis. Data from the Phase 1b BroADen study showed that KT-621 delivered substantial STAT6 degradation in both the 100 mg and 200 mg dosing groups, with median…

Kamada Ltd. (NASDAQ:KMDA) fell 8% on Monday after the company said it is discontinuing its Phase 3 trial evaluating its inhaled Alpha-1 Antitrypsin (AAT) therapy for treating Alpha-1 Antitrypsin Deficiency (AATD). The move came after guidance from an independent Data and Safety Monitoring Board, which concluded the study was unlikely to reach statistical significance on…

Fulcrum Therapeutics (NASDAQ:FULC) soared 50% on Monday after unveiling upbeat preliminary findings from its Phase 1b PIONEER study evaluating pociredir in patients with sickle cell disease. The biotech reported that the 20 mg cohort delivered a strong increase in fetal hemoglobin (HbF). By Week 6, mean absolute HbF had risen 9.9%—notably higher than the 5.6%…

Agios Pharmaceuticals (NASDAQ:AGIO) dropped 7% after revealing that the U.S. Food and Drug Administration has yet to issue a ruling on its supplemental New Drug Application (sNDA) for mitapivat. The filing seeks expanded approval for mitapivat to treat adults with both non–transfusion-dependent and transfusion-dependent forms of alpha- and beta-thalassemia. Although the application cleared its Prescription…

Strategy Inc. (NASDAQ:MSTR) revealed on Dec. 8, 2025, that it bought an additional 10,624 Bitcoin (COIN:BTCUSD) between Dec. 1 and Dec. 7, spending roughly $962.7 million. The company said the purchases were executed at an average price of $90,615 per coin. The acquisition was funded through proceeds raised under Strategy’s at-the-market (ATM) equity offering program.…